ABLYNX TO PRESENT PRE-CLINICAL PROOF-OF-CONCEPT RESULTS WITH ANTI-RSV NANOBODY, ALX-0171, AT 9th
ALX-0171 has first-in-class potential for the treatment of RSV infections On track to start first-in-infant Phase IIa study before the end of 2014 Google Anzeigen GHENT, Belgium, 6 November 2014 – Ablynx[Euronext Brussels: ABLX] …